肺痨灵合剂联合常规治疗初治肺结核疗效与安全性研究

发布时间：2018-11-06 15:15

【摘要】：目的观察免疫类中药协定处方——肺痨灵合剂治疗肺结核的临床疗效及安全性。方法将120例肺结核患者,随机分为治疗组(n=60)和对照组(n=60)。治疗组用肺痨灵合剂加常规抗结核药治疗,并与单纯常规抗结核药治疗进行对照。观察两组临床疗效、病灶吸收和药物不良反应等情况。结果在6个月疗程结束后治疗组临床症状改善情况优于对照组;两组2个月、6个月后痰菌转阴率及空洞闭合数无差异(P0.05);但治疗组在治疗咯血、病灶吸收、白细胞降低、肝功能损害方面优于对照组,两组间比较差异显著(P0.05);而在严重胃肠道反应方面,治疗组明显优于对照组,差异显著(P0.01)。结论肺痨灵合剂配合化学药常规抗痨治疗利于促进病灶吸收,明显减轻化学药不良反应,具有一定的临床价值。
[Abstract]:Objective to observe the clinical efficacy and safety of Huiyuiling mixture, a traditional Chinese medicine prescription for immunology, in the treatment of pulmonary tuberculosis. Methods 120 patients with pulmonary tuberculosis were randomly divided into treatment group (n = 60) and control group (n = 60). The treatment group was treated with Hutaoling mixture and routine antituberculous agents, and compared with only routine antituberculous agents. The clinical efficacy, focus absorption and adverse drug reactions were observed in the two groups. Results the improvement of clinical symptoms in the treatment group was better than that in the control group after 6 months of treatment, and there was no difference in the sputum negative rate and cavity closure between the two groups after 2 months and 6 months (P0.05). But the treatment group in the treatment of hemoptysis, focus absorption, leukopenia, liver function damage than the control group, there was a significant difference between the two groups (P0.05); In severe gastrointestinal reaction, the treatment group was significantly better than the control group, the difference was significant (P0.01). Conclusion the combination of Huiyuiling mixture and conventional antituberculous therapy is beneficial to promote the absorption of the focus and alleviate the adverse reaction of the chemical drug obviously, which has certain clinical value.
【作者单位】：丽水市中医医院;
【基金】：浙江省医学会临床科研基金项目(2012ZYC-B4)
【分类号】：R521

【参考文献】